Oxford Biomedica plc Stock price

Equities

OXB

GB00BDFBVT43

Biotechnology & Medical Research

Market Closed - London S.E. 12:35:07 2024-03-28 pm EDT 5-day change 1st Jan Change
201 GBX +1.93% Intraday chart for Oxford Biomedica plc +3.18% -8.64%
Sales 2023 * 90.32M 114M Sales 2024 * 130M 164M Capitalization 201M 254M
Net income 2023 * -89M -112M Net income 2024 * -38M -47.97M EV / Sales 2023 * 1.71 x
Net cash position 2023 * 46.24M 58.37M Net cash position 2024 * 12.81M 16.17M EV / Sales 2024 * 1.45 x
P/E ratio 2023 *
-2.21 x
P/E ratio 2024 *
-5.22 x
Employees 891
Yield 2023 *
-
Yield 2024 *
-
Free-Float 80.8%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.93%
1 week+3.18%
Current month+16.86%
1 month+16.72%
3 months-7.59%
6 months-32.32%
Current year-8.64%
More quotes
1 week
187.20
Extreme 187.2
202.50
1 month
167.00
Extreme 167
220.00
Current year
167.00
Extreme 167
220.00
1 year
164.29
Extreme 164.288
474.50
3 years
164.29
Extreme 164.288
1 678.00
5 years
164.29
Extreme 164.288
1 678.00
10 years
88.70
Extreme 88.7
1 678.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 23-03-26
Director of Finance/CFO 52 17-08-28
Chairman 68 20-06-23
Members of the board TitleAgeSince
Director/Board Member 61 23-04-30
Chairman 68 20-06-23
Director/Board Member 66 16-05-31
More insiders
Date Price Change Volume
24-03-28 201 +1.93% 240,015
24-03-27 197.2 +1.34% 213,723
24-03-26 194.6 +0.10% 416,326
24-03-25 194.4 -1.22% 225,510
24-03-22 196.8 +1.03% 208,090

Delayed Quote London S.E., March 28, 2024 at 12:35 pm EDT

More quotes
Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
2.01 GBP
Average target price
4.154 GBP
Spread / Average Target
+106.65%
Consensus
  1. Stock
  2. Equities
  3. Stock Oxford Biomedica plc - London S.E.